Research programme: biosimilars - PanGen Biotech

Drug Profile

Research programme: biosimilars - PanGen Biotech

Alternative Names: Adalimumab biosimilar - pangen biotech; Bevacizumab biosimilar - pangen biotech; Cetuximab biosimilar - pangen biotech; Etanercept biosimilar - Pangen biotech; Human blood coagulation factor IX - PanGen Biotech; Human blood coagulation factor VIII - PanGen Biotech; Human bone morphogenetic protein-2 - PanGen Biotech; Human bone morphogenetic protein-4 - PanGen Biotech; Human bone morphogenetic protein-7 - PanGen Biotech; Human erythropoietin - PanGen Biotech; Human follicle stimulating hormone - PanGen Biotech; Human granulocyte colony stimulating factor - PanGen Biotech; Human granulocyte macrophage colony stimulating factor - PanGen Biotech; Human growth hormone - PanGen Biotech; Human hepatocyte growth factor - PanGen Biotech; Human interferon-alpha - PanGen Biotech; Human interferon-beta - PanGen Biotech; Human interferon-gamma - PanGen Biotech; Human interleukin-10 - PanGen Biotech; Human interleukin-11 - PanGen Biotech; Human interleukin-12 - PanGen Biotech; Human interleukin-2 - PanGen Biotech; Human interleukin-3 - PanGen Biotech; Human interleukin-4 - PanGen Biotech; Human interleukin-6 - PanGen Biotech; Human luteinizing hormone - PanGen Biotech; Human thrombopoietin - PanGen Biotech; Human thyroid stimulating hormone - PanGen Biotech; Human transforming growth factor beta 3 - PanGen Biotech; Human tumour necrosis factor alpha - PanGen Biotech; Human vascular endothelial growth factor 165 - PanGen Biotech; Infliximab biosimilar- PanGen Biotech; PGA101; PGA102; PGA103; PGA104; PGA105; PGA106; PGA107; PGA109; PGA110; PGA111; PGA112; PGA113; PGA114; PGA115; PGA116; PGA117; PGA118; PGA119; PGA120; PGA131; PGB202; PGB204; PGB205; PGC301; PGC302; PGC303; PGC304; PGC305; PGF602; PGF603; PGF604; PGF605; PGF606; PGF607; PGF608; Rituximab biosimilar - PanGen Biotech; Trastuzumab biosimilar - PanGen Biotech

Latest Information Update: 23 Jun 2015

Price : $50

At a glance

  • Originator PanGen Biotech
  • Class Blood coagulation factors; Colony-stimulating factors; Follicle stimulating hormones; Glycoproteins; Growth factors; Monoclonal antibodies; Pituitary gonadotropins; Recombinant fusion proteins; Recombinant proteins; Transforming growth factors
  • Mechanism of Action Angiogenesis inhibitors; B cell inhibitors; B cell stimulants; Blood coagulation factor replacements; CD20 antigen inhibitors; Epidermal growth factor inhibitors; ERBB 2 receptor antagonists; Erythropoiesis stimulants; Factor IX stimulants; Factor VII stimulants; Granulocyte colony stimulating factor stimulants; Granulocyte macrophage colony stimulating factor agonists; Immunomodulators; Immunostimulants; Immunosuppressants; Interferon alpha stimulants; Interferon gamma stimulants; Interleukin 10 stimulants; Interleukin 11 stimulants; Interleukin 2 stimulants; Interleukin 3 stimulants; Interleukin 4 receptor agonists; Interleukin 6 receptor modulators; Osteogenesis stimulants; Ovarian follicle stimulants; Somatotropin receptor agonists; Thrombopoietin stimulants; Thyrotropin releasing hormone stimulants; Transforming growth factor beta3 stimulants; Tumour necrosis factor alpha inhibitors; Tumour necrosis factor inhibitors; Tumour necrosis factor stimulants; Vascular endothelial growth factor A inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Anaemia; Bone disorders; Cancer; Haematological disorders; Immunological disorders; Infertility; Inflammation; Mouth disorders; Neutropenia; Rheumatic disorders; Skin disorders; Somatotropin deficiency; Thyroid cancer; Viral infections; Xenotransplant rejection

Most Recent Events

  • 09 Jun 2015 Early research in Anaemia, Bone disorders, Cancer, Haematological disorders, Immunological disorders, Infertility, Inflammation, Mouth disorders, Neutropenia, Rheumatic disorders, Skin disorders, Somatotropin deficiency, Thyroid cancer, Viral infections, Xenotransplant rejection in South Korea (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top